Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 4:58 pm Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Citadel Advisors LLC | 5,334,112 9.600% | 3,249,845 (+155.92%) | Filing History |
| 2025-08-14 3:51 pm Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Vestal Point Capital, LP | 3,228,161 6.000% | 3,228,161 (New Position) | Filing History |
| 2025-08-14 1:40 pm Sale | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Frazier Life Sciences Public Fund, L.P. | 3,073,467 5.700% | -2,427,345 (-44.13%) | Filing History |
| 2025-08-14 11:46 am Sale | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | JANUS HENDERSON GROUP PLC JHG | 3,684,383 11.100% | -873,537 (-19.17%) | Filing History |
| 2025-08-14 06:40 am Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Balyasny Asset Management L.P. | 8,345,651 9.990% | 8,345,651 (New Position) | Filing History |
| 2025-08-07 4:18 pm Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Integrated Core Strategies (US) LLC | 2,836,292 5.300% | 902,913 (+46.70%) | Filing History |
| 2025-06-04 4:51 pm Purchase | 2025-05-28 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Frazier Life Sciences Public Fund, L.P. | 5,500,812 9.900% | 5,500,812 (New Position) | Filing History |
| 2025-06-04 4:04 pm Purchase | 2025-05-28 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Affinity Healthcare Fund, LP | 4,252,005 7.750% | 4,252,005 (New Position) | Filing History |
| 2025-05-15 09:58 am Sale | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | D1 Capital Partners L.P. | 978,652 2.900% | -1,527,955 (-60.96%) | Filing History |
| 2025-05-14 12:00 pm Purchase | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | JANUS HENDERSON GROUP PLC JHG | 4,557,920 13.700% | 218,666 (+5.04%) | Filing History |
| 2025-05-13 06:55 am Purchase | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | MIZUHO FINANCIAL GROUP INC | 2,203,631 6.600% | 276,700 (+14.36%) | Filing History |
| 2025-05-12 09:00 am Sale | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Adage Capital Management, L.P. | 237,953 0.700% | -1,971,662 (-89.23%) | Filing History |
| 2025-04-28 4:03 pm Purchase | 2025-04-22 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Integrated Core Strategies (US) LLC | 1,933,379 5.800% | 1,933,379 (New Position) | Filing History |
| 2025-02-14 12:03 pm Sale | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Eventide Asset Management, LLC | 1,234,834 3.730% | -621,152 (-33.47%) | Filing History |
| 2025-02-14 11:55 am Purchase | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | JANUS HENDERSON GROUP PLC JHG | 4,339,254 13.100% | 576,059 (+15.31%) | Filing History |
| 2025-02-14 09:00 am Sale | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Omega Fund VI, L.P. | 1,184,636 3.600% | -972,987 (-45.10%) | Filing History |
| 2025-02-13 10:24 am Purchase | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | MIZUHO FINANCIAL GROUP INC | 1,926,931 5.800% | 1,926,931 (New Position) | Filing History |
| 2025-02-12 09:35 am Sale | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Adage Capital Management, L.P. | 2,209,615 6.680% | -388,121 (-14.94%) | Filing History |
| 2025-02-04 3:45 pm Purchase | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | BlackRock Inc. BLK | 1,821,966 5.500% | 1,821,966 (New Position) | Filing History |
| 2024-11-14 5:49 pm Sale | 2024-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Lundbeckfond Invest A/S | 942,671 2.900% | -893,288 (-48.66%) | Filing History |